Page 189 - Read Online

Saneto. J Transl Genet Genom 2020;4:384-428 I http://dx.doi.org/10.20517/jtgg.2020.40 Page 417

10. Gorman GS, Schaefer AM, Ng Y, Gomez N, Blakely EL, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult
mitochondrial disease. Ann Neurol 2015;77:753-59.
11. Skladal D, Halliday J, Thorborn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain
2003;126:1905-12.
12. Frazier AE, Thorburn DR, Compton AG. Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. J Biol
Chem 2019;294:5386-95.
13. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatr 1951;14:216-21.
14. Bernier FP, Boneh A, Dennett X, Chow CW, Cleary MA, et al. Diagnostic criteria for respiratory chain disorder in adults and children.
Neurology 2002;59:1406-11.
15. Spiro AJ, Moore CL, Prineas JW, Stasberg PM, Rapin I. A cytochrome-related inherited disorder of the nervous system and muscle. Arch
Neurol 1970;23:103-12.
16. Willems JL, Monnens L, Trijbels J, Veerkamp JH, Meyer A, et al. Leigh’s encephalomyelopathy in a patient with cytochrome c oxidase
deficiency in muscle tissue. Pediatrics 1977;60:850-7.
17. Shapira Y, Harel S, Russell A. Mitochondrial encephalopmyopathies: A group of neuromuscular disorders with defects in oxidative
metabolism. Israel J of Med Sci 1977;13:161-4.
18. Rodenburg RJ, Schoonderwoerd GC, Tiranti V, Taylor RW, Rotig A, et al. A multi-center comparison of diagnostic methods for the
biochemical evaluation of suspected mitochondrial disorders. Mitochondrion 2013;13:36-43.
19. Chen X, Thorburn DR, Wong LJ, Vladutiu G, Haas RH, et al. Quality improvement of mitochondrial respiratory chain complex enzyme
assays using Caenorhabditis Elegans. Genet Med 2011;13:794-9.
20. Witters P, Saada A, Honzik T, Tesarova M, Kleinle S, et al. Revisiting mitochondrial diagnostic criteria in the new era of genomics. Genet
Med 2018;20:444-51.
21. Bai RK, Wong LJ. Detection and quantification of heteroplasmic mutant mitochondrial DNA by real-time amplification refractory
mutation system quantitative PCR analysis: a single-step approach. Clin Chem 2004;50:996-1001.
22. Tang S, Wang J, Zhang VW, Li FY, Landsverk M, et al. Transition to next generation analysis of the whole mitochondrial genome: a
summary of molecular defects. Hum Mut 2013;34:882-93.
23. Saneto RP. Genetics of mitochondrial disease. Adv Genet 2017;98:63-116.
24. Calvo SE, Mootha VK. The mitochondrial proteome and human disease. Ann Rev Genomics Hum Genet 2010;11:25-44.
25. Calvo SE, Clauser KR, Mootha VK. MitoCarta2.0: an updated inventory of mammalian mitochondrial proteins. Nucleic Acids Res
2016;44:D1251-7.
26. DaRe JT, Vasta V, Penn J, Tran NTB, Hahn SH. Targeted exome sequencing for mitochondrial disorders reveals high genetic
heterogeneity. BMC Med Genet 2013:11:14:118.
27. Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, et al. Practice patterns of mitochondrial disease physicians in North America.
Part I: diagnostic and clinical challenges. Mitochondrion 2014;14:26-33.
28. Thompson K, Collier JJ, Glasgow RIC, Robertson FM, Pyle A, et al. Recent advances in understanding the molecular genetic basis of
mitochondrial disease. J Inherit Metab Dis 2019;43:36-50.
29. Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, et al. Deleterious-and disease-allele prevalence in healthy individuals: insights from current
predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 2012;91:1022-31.
30. Strande NT, Riggs ER, Buchanan AH, Ceyhan-Birsoy O, et al. Evaluating the clinical validity of gene-disease associations: an evidence-
based framework developed by the Clinical Genome Resource. Am J Hum Genet 2017;100:895-906.
31. Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, et al. ClinGen-The clinical genome resource. N Engl J Med 2015;372:2235-42.
32. Richards S, Aziz N, Bale S, Bick D, Das S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med
2015;17:405-24.
33. Saneto RP, Naviaux RK. Polymerase gamma disease through the ages. Dev Disabil Res Rev 2010;16:163-74.
34. Saneto RP, Lee IC, Koenig MK, Bao X, Weng SW, et al. POLG DNA testing as an emerging standard of care before institution of
valproic acid therapy for pediatric seizure disorders. Seizure 2010;19:140-6.
35. Yamanaka H, Gatanaaga H, Kosalaraksa P, Matsuoka-Aizawa S, Takahashi T, et al. Novel mutation of human DNA polymerase g
associated with mitochondrial toxicity induced by anti-HIV treatment. J Infect Dis 2007;195:1419-25.
36. Cai W, Fu Q, Zhou X, Qu J, Tong Y, et al. Mitochondrial variants may influence the phenotypic manifestation of Leber’s hereditary optic
neuropathy-associated ND4 G11778A mutation. J Genet Genomics 2008;35:649-55.
37. Mitchell AL, Elison JL, Howell N, Taylor RW, Turnbull DM. Sequence variation in mitochondrial complex I genes; mutation or
polymorphism. J Med Genet 2006;43:175-9.
38. Shoffner JM, Lott MT, Lezza AMS, Seibel P, Ballinger SW, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated
with a mitochondrial DNA tRNA(lys) mutation. Cell 1990;61:931-7.
39. Boczonadi V, Jennings MJ, Horvath R. The role of tRNA synthetases in neurological and neuromuscular disorders. FEBS Lett
2018;592:703-17.
40. DiMauro S, Schon EA, Carelli V, Hirano M. The clinical maze of mitochondrial neurology. Nat Rev Neurol 2013;9:429-44.
41. Archer SL. Mitochondrial dynamics-mitochondrial fission and fusion in human diseases. N Engl J Med 2013;369:2236-51.
42. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, et al. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest
mitochondrial motility. Cell 2011;147:893-906.